metricas
covid
Annals of Hepatology Neutrophil-lymphocyte ratio as a prognostic factor in patients with alcoholic he...
Journal Information
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Full text access
Neutrophil-lymphocyte ratio as a prognostic factor in patients with alcoholic hepatitis.
Visits
446
Moises Coutiño-Flores1, Jesús I. Mazadiego-Cid1, Rogelio Zapata-Arenas3, Katy A. Sánchez-Pozos2, Antonio Coutiño-Flores2, María R. Herrero-Maceda1, Scherezada M.I. Mejía-Loza1
1 Gastroenterology, Juarez Hospital, Mexico
2 Research Division, Juarez Hospital of Mexico
3 Internal Medicine, General Hospital of Mexico Dr. Eduardo Liceaga, Mexico
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Comparison of clinical data and severity scales between surviving and non-surviving subjects at 28 days.
Tables
Special issue
This article is part of special issue:
Vol. 30. Issue S1

Abstracts Asociación Mexicana de Hepatología (AMH) 2024

More info
Introduction and Objectives

The neutrophil-lymphocyte ratio (NLR) has been used as a predictor of survival in critically ill patients. However, there are scarce studies that evaluate the relationship between NLR and alcoholic hepatitis. Thus, we aimed to determine the association between NLR with mortality and the degree of acute-on-chronic liver failure (ACLF).

Materials and Patients

Longitudinal, retrospective, observational and descriptive cohort study of a hospital center. Patients who attended from March 1, 2022, to April 30, 2024, to Gastroenterology service were included. The subjects met criteria for alcohol hepatitis established by the National Institute on Alcohol Abuse and Alcoholism: alcohol consumption >40 g/day (women) or >60 g/day (men) for six or more months, jaundice during the previous eight weeks, AST > 50 IU/L, AST/ALT ratio > 1.5, and both values ​​< 400 IU/L, BT > 3.0 mg/dL. Patients with concomitant infections or conditions that could alter the NLR (steroid use, pancreatitis, hemorrhage, neoplasms) were excluded. Statistical analysis was performed with the SPSS version 26 program. To compare clinical values, Student's T-test or Mann Whitney U test were performed according to the distribution of the data. The association analysis between NLR and 30-day mortality, as well as the association between NLR and ACLF degrees, were carried out using a point-biserial correlation. Cohen's d test was performed to determine the effect size.

Results

This study included 58 patients with alcoholic hepatis (98% men). The mean of the INL was 24.3. There was significant difference between patients who died within 28 days compared with those who survived (Table 1). The main differences were observed in the following data: leukocytes (p < 0.001), creatinine levels (p = 0.007), BT (p < 0.001); as well as, in the indexes: INL (p < 0.001), CLIF SCORE (p <0.001), MELD (p = 0.02) and MELD Na (p = 0.01). (Table 1). The mean NLR value in patients who survived was approximately three times the value presented in patients who died within 28 days [23.0 (19.1, 28.6) vs. 8.0 (5.0, 11.0); (p < 0.001)]. A gradual increase in severity-dependent NLR was identified based on the CLIF SCORE scale (significant difference among the three groups considering CLIF SCORE 0). In addition, significant associations between NLR and 28-day mortality (p < 0.001), and between NLR and the degree of ACLF (p < 0.001) were found. According to Cohen's test, the effect size of the NLR was moderate (0.678).

Conclusions

The association between high NLR levels and mortality within 28 days is confirmed. Furthermore, there is an association between NLR and the severity of ACLF. Therefore, the NLR could be a useful prognostic factor in the clinical practice for alcoholic hepatitis. However, more studies with larger sample sizes are required.

Full Text

Ethical statement: The protocol was registered and approved by the Ethics Committee. Patient confidentiality was maintained, and informed consent was obtained.

Declaration of interests: None.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Table 1.

Comparison of clinical data and severity scales between surviving and non-surviving subjects at 28 days.

Variable  Death in the first 28 days (n=33)  Survivors after 28 days (n=25)  p 
Age  46.0 ± 8.7  41.8 ± 10.1  0.094 
Leukocytes  21.6 (15.0, 29.6)  9.6 (7.7, 13.2)  < 0.001 
Platelets  168.9 ± 97.1  138.8 ± 91.9  0.234 
PT  23.0 (19.1, 28.6)  22.2 (17.9, 25.7)  0.236 
BT  24.4 ± 9.3  15.0 ± 10.1  < 0.001 
INR  2.00 (1.79, 2.70)  1.94 (1.50, 2.27)  0.118 
Cr  2.16 (1.30, 3.19)  1.30 (0.82, 2.09)  0.007 
NLR  23.0 (18.0, 34.0)  8.0 (5.0, 11.0)  < 0.001 
CLIF SCORE  56.18 ± 6.28  46.88 ± 6.35  < 0.001 
MADDREY  71.3 (55.3, 99.1)  65.6 (33.4, 74.5)  0.059 
MELD  35.7 ± 12.5  25.0 ± 8.6  < 0.001 
MELD NA  39.2 ± 15.8  29.7 ± 13.8  0.021 

BT, Total bilirubin; CLIF SCORE, Chronic Liver Failure score; Cr, Creatinine; INR, International Normalized Ratio; MADDREY, Maddrey's discriminant function; MELD, Model for End-Stage Liver Disease; MELD NA, MELD sodium; NLR, Neutrophil-lymphocyte ratio; PT, Prothrombin Time.

Download PDF
Article options
Tools